Bonk (BONK) is currently trading at $0.00001010, registering a mild 0.16% gain. Despite the marginal upward movement, trading activity softened, with 24-hour volume slipping 20.57% to $91.63 million. Over the past week, however, BONK has demonstrated quiet resilience, advancing 3.97% and maintaining its stance above key market levels. The current market mood reflects cautious consolidation […]Bonk (BONK) is currently trading at $0.00001010, registering a mild 0.16% gain. Despite the marginal upward movement, trading activity softened, with 24-hour volume slipping 20.57% to $91.63 million. Over the past week, however, BONK has demonstrated quiet resilience, advancing 3.97% and maintaining its stance above key market levels. The current market mood reflects cautious consolidation […]

BONK Price Surge Ahead? Powerful Rally Targets $0.000039

  • BONK holds steady above key technical support as bullish momentum quietly builds.
  • Analysts highlight multiple upside targets, citing strengthening mid-term structure.
  • Market forecasts for 2025 present a broad but optimistic price range across major platforms.

Bonk (BONK) is currently trading at $0.00001010, registering a mild 0.16% gain. Despite the marginal upward movement, trading activity softened, with 24-hour volume slipping 20.57% to $91.63 million. Over the past week, however, BONK has demonstrated quiet resilience, advancing 3.97% and maintaining its stance above key market levels.

The current market mood reflects cautious consolidation rather than aggressive accumulation, yet analysts note that this type of structural pause often precedes decisive market shifts. BONK’s ability to hold its ground, despite declining volume, signals continued interest from strategic investors rather than speculative short-term traders.

BONK Holds Strong Above Key Descending Channel Support

Crypto analyst Jonathan Carter reports that BONK is firmly consolidating above the lower boundary of its descending channel on the two-day timeframe. According to his assessment, buyers are actively defending this critical support region, creating conditions that often precede a medium-term bullish reversal.

Carter emphasizes that “support hold + momentum building = midterm rally brewing,” highlighting a sequence that has historically led to notable price expansions within similar market structures. 

His forward targets outline a series of potential breakouts at $0.00001300, $0.00001970, $0.00002600, and $0.00003900, suggesting progressive resistance levels where upward momentum may either strengthen or consolidate.

The analyst adds that smart money appears to be positioning early, taking advantage of the calm phase before a potential shift in trend trajectory. This reinforces the view that BONK’s recent stabilizing behavior could be more strategic than stagnant.

Also Read | BONK Price Outlook: Can It Smash $0.00002600 and Hit $0.00003900?

BONK Price Prediction for 2025

According to DigitalCoinPrice, BONK may surpass the $0.0000221 mark by year-end, projecting a possible retest of former highs near $0.0000591. Analysts from the platform suggest that BONK could stabilize between $0.0000214 and $0.0000221, should broader market conditions remain supportive.

Meanwhile, projections from Changelly offer a more structured technical range for 2025. Their analysis positions BONK’s potential floor at $0.00002422, with a ceiling of $0.00002648 and an expected average near $0.00002533, representing a potentially robust ROI of 166.5%. For November 2025 alone, Changelly estimates a narrower spread: a minimum of $0.00000976 and a maximum of $0.00002533, maintaining an optimistic 155% potential return.

Also Read | BONK Bulls Charge Ahead: Can Price Smash $0.00003850 Resistance?

Market Opportunity
Bonk Logo
Bonk Price(BONK)
$0.000010527
$0.000010527$0.000010527
-0.94%
USD
Bonk (BONK) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26